Molbio Diagnostics shares rose over 5% on October 1, after HDFC Mutual Fund acquired a 1.99% stake. The stock gained approximately 71% since its IPO, and Jefferies assigned a ‘Buy’ rating, setting a target price of ₹1,600, indicating over 98% upside potential.